Progyny, Inc. (PGNY) Quick Ratio
- Quick ratio · latest quarter: Value 2.06×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.06× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $494.40M ÷ $240.08M ≈ 2.06× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 494.40M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 240.08M USD | Liabilities, Current |
| Cash and equivalents | 152.63M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 84.29M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 257.48M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $494.40M | $240.08M | $152.63M | $84.29M | $257.48M | (m) | 2.06× |
| 2026-03-31 | $488.72M | $235.74M | $131.61M | $93.50M | $263.61M | (m) | 2.07× |
| 2025-12-31 | $530.38M | $202.39M | $112.24M | $197.86M | $220.29M | (m) | 2.62× |
| 2025-09-30 | $597.71M | $210.49M | $133.98M | $211.22M | $252.50M | (m) | 2.84× |
| 2025-06-30 | $576.95M | $220.42M | $132.51M | $172.59M | $271.85M | (m) | 2.62× |
| 2025-03-31 | $555.87M | $237.13M | $109.24M | $146.88M | $299.74M | (m) | 2.34× |
| 2024-12-31 | $463.28M | $168.63M | $162.31M | $65.64M | $235.32M | (m) | 2.75× |
| 2024-09-30 | $516.44M | $208.47M | $91.48M | $144.24M | $280.72M | (m) | 2.48× |
| 2024-06-30 | $555.98M | $225.38M | $94.96M | $167.23M | $293.80M | (m) | 2.47× |
| 2024-03-31 | $669.04M | $205.92M | $114.96M | $256.87M | $297.21M | (m) | 3.25× |
| 2023-12-31 | $612.96M | $185.95M | $97.30M | $273.79M | $241.87M | (m) | 3.30× |
| 2023-09-30 | $604.32M | $193.42M | $158.07M | $177.48M | $268.77M | (m) | 3.12× |
| 2023-06-30 | $547.45M | $193.90M | $170.57M | $111.92M | $264.96M | (m) | 2.82× |
| 2023-03-31 | $521.13M | $206.87M | $155.32M | $52.57M | $313.25M | (m) | 2.52× |
| 2022-12-31 | $429.37M | $159.54M | $120.08M | $69.22M | $240.07M | (m) | 2.69× |
| 2022-09-30 | $399.03M | $156.87M | $72.52M | $68.47M | $258.04M | (m) | 2.54× |
| 2022-06-30 | $352.25M | $144.90M | $54.73M | $67.66M | $229.86M | (m) | 2.43× |
| 2022-03-31 | $303.80M | $128.72M | $38.82M | $66.86M | $198.12M | (m) | 2.36× |
| 2021-12-31 | $253.97M | $98.82M | $91.41M | $28.00M | $134.56M | (m) | 2.57× |
| 2021-09-30 | $249.49M | $104.48M | $92.22M | $22.09M | $135.18M | (m) | 2.39× |
| 2021-06-30 | $234.74M | $98.78M | $48.75M | $45.22M | $140.77M | (m) | 2.38× |
| 2021-03-31 | $223.58M | $101.00M | $29.82M | $77.09M | $116.67M | (m) | 2.21× |
| 2020-12-31 | $184.96M | $77.79M | $70.31M | $38.99M | $75.66M | (m) | 2.38× |
| 2020-09-30 | $183.26M | $74.17M | $53.97M | $50.99M | $78.30M | (m) | 2.47× |
| 2020-06-30 | $156.37M | $57.67M | $49.39M | $41.98M | $65.00M | (m) | 2.71× |
| 2020-03-31 | (m) | $59.06M | $91.63M | (m) | $65.86M | (m) | (m) |
| 2019-12-31 | (m) | $36.16M | $80.38M | (m) | $47.06M | (m) | (m) |
| 2019-09-30 | (m) | $57.56M | $7.66M | (m) | $44.34M | (m) | (m) |
| 2018-12-31 | (m) | $30.20M | $127.00K | (m) | $23.32M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |